Evidence map›Paper›PMID 42756844›Full record

ArticleACS omega2026

Optimized Multi-Phosphorothioate Linkers Enable Efficient Iodine-Induced Cleavage of Surface-Immobilized DNA for Genomic Applications.

Qiqi Cai, Zijie Xiao, Qingbin Chen, JieCheng Xu, Huihua Xia, Luyang Zhao, Erkai Liu, Shuguang Xuan

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qiqi CaiShenzhen Salus BioMed Co., Ltd., Shenzhen, Guangdong 518106, China.
Zijie XiaoShenzhen Salus BioMed Co., Ltd., Shenzhen, Guangdong 518106, China.
Qingbin ChenShenzhen Salus BioMed Co., Ltd., Shenzhen, Guangdong 518106, China.
JieCheng XuShenzhen Salus BioMed Co., Ltd., Shenzhen, Guangdong 518106, China.
Huihua XiaShenzhen Salus BioMed Co., Ltd., Shenzhen, Guangdong 518106, China.
Luyang ZhaoShenzhen Salus BioMed Co., Ltd., Shenzhen, Guangdong 518106, China.
Erkai LiuShenzhen Salus BioMed Co., Ltd., Shenzhen, Guangdong 518106, China.
Shuguang XuanShenzhen Salus BioMed Co., Ltd., Shenzhen, Guangdong 518106, China.ORCID https://orcid.org/0009-0001-7491-0694

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Efficient solid-phase DNA cleavage is essential for advanced biotechnology. In this study, we employed multiple phosphorothioate (PT) modifications within the DNA backbone to achieve a cleavage efficiency of >93% under mild conditions on a biochip surface. This method was successfully implemented in a next-generation sequencing (NGS) workflow as a promising alternative to the conventional 8-oxoG/formamidopyrimidine DNA glycosylase (FPG) enzymatic system. By optimizing the PT modification sites and reaction conditions, our platform delivered sequencing data quality, including Q30 scores, single-nucleotide polymorphism (SNP), and insertions and deletions (INDEL) accuracy, equivalent to established standards. Additionally, the mild reaction conditions are compatible with downstream polymerase chain reaction (PCR) amplification, enabling the process to bypass the traditional purification steps. This highly efficient, cost-effective chemical cleavage approach facilitates seamless integration into automated genomic analysis platforms and streamlined molecular diagnostics.

Identifiers

PMID42756844
PMCPMC13584795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.